NASDAQ:ADTX

Aditxt Q2 2025 Earnings Results & Report

Aditxt logo
$0.0002 0.00 (0.00%)
As of 03:57 PM Eastern

Aditxt reported Q2 2025 earnings on August 14, 2025. The company reported EPS of -$84,207.60.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Aditxt EPS Results

Actual EPS
-$84,207.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Aditxt's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Aditxt Q2 2025 Earnings FAQ

Aditxt (NASDAQ:ADTX) reported earnings of -$84,207.60 per share for Q2 2025. The report was announced on Thursday, August 14, 2025.

Aditxt's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aditxt on the company's earnings history page.

Aditxt Earnings Headlines

Aditxt Faces Nasdaq Delisting, Moves Fully to OTC
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Aditxt Stock Dividends | NASDAQ:ADTX | Benzinga
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX) is a biotechnology company focused on developing technologies for immune-system monitoring and modulation. Its AditxtScore platform is designed to measure and profile immune responses, with potential applications in tracking immune health and supporting personalized care.

The company has also pursued immune-reprogramming approaches intended to promote immune tolerance in areas such as autoimmune disease, allergies and transplant rejection. Through its operating businesses and strategic initiatives, Aditxt has expanded its activities into diagnostics and other health-related technologies.

View Aditxt Profile